New combo treatment aims to keep aggressive lung cancer from returning after surgery
NCT ID NCT07149363
Summary
This study is testing if adding an immunotherapy drug (durvalumab) to standard chemotherapy after surgery helps keep early-stage small cell lung cancer from coming back. It will enroll about 65 adults whose cancer was completely removed by surgery. The main goal is to see if this combination leads to longer survival without the cancer returning compared to historical data for chemotherapy alone.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER (SCLC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Virginia Comprehensive Cancer Center
RECRUITINGCharlottesville, Virginia, 22908, United States
Conditions
Explore the condition pages connected to this study.